On November 16, 2015 Private clinical swelling dedicated to the development of new cancer therapies The cancer research company Tragara Pharmaceuticals (Tragara Pharmaceuticals, Inc., hereinafter referred to as "Tragara") reported that Li China Cancer Medical Co., Ltd. (hereinafter referred to as "Li’s Pharmaceutical Factory") subsidiary of China Cancer Medical Co., Ltd. (China) Oncology Focus Limited) has obtained the TG02 concession for oral multi-kinase inhibitors granted by Tragara (Press release, Lee’s Pharmaceutical, NOV 17, 2015, View Source [SID1234532913]). Lee’s Pharmaceutical Factory Is a biopharmaceutical company listed on the main board of the Hong Kong Stock Exchange (stock code: 950), with more than 20 in the Chinese pharmaceutical industry. Year of operation history.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Lee’s Pharmaceuticals acquired exclusive rights to develop and sell TG02 in the following countries, including: China Mainland, Hong Kong, Macau, Taiwan, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines Bin, Singapore, Thailand and Vietnam. Tragara will receive upfront payments for prepaid cash, related potential periodic payments and The tiered royalties for net sales. Lee’s Pharmaceuticals will be responsible for the development, registration and commercialization of TG02 within its scope of license. Industrialization related expenses. In the early stages, Lee’s Pharmaceuticals will focus on the clinical development of TG02 for hepatocellular carcinoma treatment. both sides Research and development results and related data will be shared.
In the United States, TG02 is currently being combined with the new-generation protease inhibitor carfilzomib for phase 1b clinical trials in patients with multiple myeloma. Research stage. The concept has been validated in this study and Tragara will continue to recruit more patients to participate in the study. For MYC- The first phase of over-expressed solid tumors is in the planning stage.
Tragara also announced today that the company recently completed a $13 million Series C private placement financing. Lee’s Pharmaceutical Factory and Existing investors have participated in the financing, including investors in Domain Associates Ventures, Morgan Taylor Venture capital firms (Morgenthaler Ventures), ProQuest Investments investment companies and RusnanoMedInvest Investment Company.
"We are honored to work with Tragara to develop TG02 in Greater China and Southeast Asia. I believe TG02 will be very A new treatment option for patients with multiple hepatocellular carcinoma (HCC)." Dr. Li Xiaoyu, Chief Executive Officer and Executive Director of Lee’s Pharmaceuticals "We are currently developing a PD-L1 monoclonal antibody, an oncolytic virus and a proprietary chemical, plus one Targeted therapeutics, which will give our group a dominant position in the field of cancer treatment, and successfully self-developed combined drugs. "
"We are very pleased to work with Lee’s Pharmaceuticals to develop and accelerate the development of TG02 on a global scale. This collaboration is not only About the development of TG02 for the treatment of hepatocellular carcinoma (HCC), and will also serve as a platform to establish an over-expression table for MYC oncogenes Clinical proof of solid tumors. We are full of expectations for cooperation with Lee’s Pharmaceuticals. President and head of Tragara Executive Officer Thomas M. Estok said.